US patent for rapid bacterial vaginosis test:
This article was originally published in Clinica
Executive Summary
Litmus Concepts has received a third US patent covering its rapid test for bacterial vaginosis (BV). The pH and Amines FemExam TestCard, which was approved by the FDA in 1997, produces a qualitative "yes/no" result, providing an objective means of diagnosing the infection. This replaces the subjective "Whiff" test, which requires the healthcare worker to smell for a characteristic amine odour, said the Santa Clara, California-based company. The new patent covers the use of the device to detect BV as a stand-alone product and when used as part of the clinical criteria for diagnosing BV.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.